跳至主要内容
临床试验/NCT04325217
NCT04325217已完成不适用

Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan

Boehringer Ingelheim1 个研究点 分布在 1 个国家目标入组 586 人开始时间: 2020年5月27日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
586
试验地点
1
主要终点
Incidence of adverse drug reactions (ADRs)

研究概览

简要总结

The primary objective is to confirm the incidence of adverse drug reactions (focus on gastrointestinal symptoms including diarrhoea and nausea) to Ofev Capsules seen in clinical trials with real world data generated in patients with SSc-ILD.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients in Japan with SSc-ILD who are prescribed with Ofev Capsules and have never been treated with Ofev Capsules before enrolment will be included.

排除标准

  • 未提供

研究组 & 干预措施

Patients newly initiating Ofev®/Nintedanib Capsules

干预措施: Nintedanib (Drug)

结局指标

主要结局

Incidence of adverse drug reactions (ADRs)

时间窗: up to 3 years and 9 months

Focus on gastrointestinal symptoms including diarrhea and nausea

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Post-marketing Surveillance on Long Term Use of Ofev... | 临床试验